The introduction of tyrosine kinase inhibitors (TKIs)6,7, immune checkpoint inhibitors (ICIs)8,9, mammalian target of rapamycin (mTOR) inhibitors10, and combinations of these anti-cancer therapies11–13, has significantly improved the outcome for patients with advanced ccRCC. Here, MTOR is linked to nonpapillary renal cell carcinoma.